Press Releases

Oct 02

Solid Biosciences to Participate in the Chardan 3rd Annual Genetic Medicines Conference

CAMBRIDGE, Mass. , Oct. 02, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) today announced that Joel Schneider , PhD., Chief Technology Officer, will participate in a webcast question and answer session at the upcoming Chardan Annual Genetic Medicines Conference at 8:30 a.m.

Read More
Sep 05

Solid Biosciences Announces Publication Highlighting the Important Role of the nNOS Domain in Microdystrophin Function and its Potential Utility in DMD Gene Therapy in the Journal Neuromuscular Disorders

CAMBRIDGE, Mass. , Sept. 05, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) today announced the publication of a review article in the journal Neuromuscular Disorders ¹ that summarizes the evidence supporting the function of microdystrophin-associated neuronal nitric oxide synthase

Read More
Aug 14

Solid Biosciences Reports Second Quarter 2019 Financial Results and Provides Business Update

– Additional patient dosed at 2E14 vg/kg in second cohort of IGNITE DMD trial – – Study protocol amended to expedite clinical execution of SGT-001 – – Recent $60M capital raise extends runway into the fourth quarter of 2020 – CAMBRIDGE, Mass. , Aug. 14, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences

Read More
Jul 26

Solid Biosciences Announces $60 Million Private Placement with New and Existing Investors

CAMBRIDGE, Mass. , July 26, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) today announced that it has entered into a securities purchase agreement with a select group of institutional investors and accredited investors for a $60 million private placement, which is expected to close

Read More
May 13

Solid Biosciences Reports First Quarter 2019 Financial Results and Provides Business Update

– Dosing of SGT-001 initiated in second cohort of patients in the IGNITE DMD clinical trial at 2E14 vg/kg – – Clinical activities underway at additional study sites – CAMBRIDGE, Mass. , May 13, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) today reported financial results for the

Read More
Apr 15

Solid Biosciences Announces Upcoming Preclinical Data Presentations at The American Society of Gene and Cell Therapy Annual Meeting

CAMBRIDGE, Mass. , April 15, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) today announced that preclinical data from its gene therapy program for Duchenne muscular dystrophy (DMD) will be presented at the 22 nd Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)

Read More
Mar 13

Solid Biosciences Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Provides Business Update

–Activities underway to commence dosing of second cohort of patients in the IGNITE DMD clinical trial at 2E14 vg/kg of SGT-001– CAMBRIDGE, Mass. , March 13, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ: SLDB) today reported financial results for the fourth quarter and fiscal year ended

Read More
Feb 07

Solid Biosciences Announces Preliminary SGT-001 Data and Intention to Dose Escalate in IGNITE DMD Clinical Trial for Duchenne Muscular Dystrophy

- Company expediting planned dose escalation activities - - Low levels of SGT-001 microdystrophin protein detected at the starting dose - - Conference call to be held at 8:30 a.m. ET today - CAMBRIDGE, Mass. , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences (Nasdaq: SLDB) announced today

Read More
Jan 02

Solid Biosciences to Present at the J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ: SLDB) today announced that Ilan Ganot , Co-Founder, Chief Executive Officer and President of Solid Biosciences will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9 th at 7:30 am

Read More

News & Events

Press Releases